Cargando…

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

BACKGROUND: Drug resistance is a common cause of treatment failure in cancer patients and encompasses a multitude of different mechanisms. The aim of the present study was to identify drugs effective on multidrug resistant cells. METHODS: The RPMI 8226 myeloma cell line and its multidrug resistant s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fryknäs, Mårten, Gullbo, Joachim, Wang, Xin, Rickardson, Linda, Jarvius, Malin, Wickström, Malin, Hassan, Saadia, Andersson, Claes, Gustafsson, Mats, Westman, Gunnar, Nygren, Peter, Linder, Stig, Larsson, Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751689/ https://www.ncbi.nlm.nih.gov/pubmed/23919498 http://dx.doi.org/10.1186/1471-2407-13-374

Ejemplares similares

Mebendazole is unique among tubulin-active drugs in activating the MEK–ERK pathway
por: Andersson, Claes R., et al.
Publicado: (2020)

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles
por: Rickardson, L, et al.
Publicado: (2005)

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
por: Eriksson, A, et al.
Publicado: (2015)

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
por: Selvin, Tove, et al.
Publicado: (2023)

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
por: Karlsson, Henning, et al.
Publicado: (2017)

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
por: Selvin, Tove, et al.
Publicado: (2022)

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation
por: Karlsson, Henning, et al.
Publicado: (2019)

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
por: Blom, Kristin, et al.
Publicado: (2019)

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
por: Ek, Frida, et al.
Publicado: (2022)

In vitro and in vivo activity of melflufen (J1)in lymphoma
por: Delforoush, Maryam, et al.
Publicado: (2016)

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
por: Zhang, Xiaonan, et al.
Publicado: (2014)

Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing
por: Rubin, Jenny, et al.
Publicado: (2018)

Effects of hypoxia on human cancer cell line chemosensitivity
por: Strese, Sara, et al.
Publicado: (2013)

Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia
por: Hallböök, Helene, et al.
Publicado: (2011)

Iron chelators target both proliferating and quiescent cancer cells
por: Fryknäs, Mårten, et al.
Publicado: (2016)

COMBImage: a modular parallel processing framework for pairwise drug combination analysis that quantifies temporal changes in label-free video microscopy movies
por: Chantzi, Efthymia, et al.
Publicado: (2018)

COMBImage2: a parallel computational framework for higher-order drug combination analysis that includes automated plate design, matched filter based object counting and temporal data mining
por: Chantzi, Efthymia, et al.
Publicado: (2019)

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
por: Andersson, Claes R., et al.
Publicado: (2022)

Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters
por: Fayad, Walid, et al.
Publicado: (2009)

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
por: Nygren, Peter, et al.
Publicado: (2013)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017)

Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
por: Dimberg, Lina Y, et al.
Publicado: (2012)

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival
por: Lu, Xi, et al.
Publicado: (2022)

Elevation of Proteasomal Substrate Levels Sensitizes Cells to Apoptosis Induced by Inhibition of Proteasomal Deubiquitinases
por: Sun, Chao, et al.
Publicado: (2014)

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
por: Karlsson, Henning, et al.
Publicado: (2022)

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15
por: Mofers, Arjan, et al.
Publicado: (2019)

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
por: Byrgazov, Konstantin, et al.
Publicado: (2020)

Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells
por: Milani, Lili, et al.
Publicado: (2007)

Improved variance estimation of classification performance via reduction of bias caused by small sample size
por: Wickenberg-Bolin, Ulrika, et al.
Publicado: (2006)

Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis
por: Das, Lalita, et al.
Publicado: (2012)

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
por: Strese, Sara, et al.
Publicado: (2016)

Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis
por: Berndtsson, Maria, et al.
Publicado: (2009)

Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism
por: Kashif, Muhammad, et al.
Publicado: (2017)

In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index
por: Kashif, M., et al.
Publicado: (2015)

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
por: Mansoori, S., et al.
Publicado: (2021)

Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth
por: Velentza, Lilly, et al.
Publicado: (2023)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
por: Gasic, Ivana, et al.
Publicado: (2020)

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index
por: Hu, Kefei, et al.
Publicado: (2010)

Integrin Involvement in Freeze Resistance of Androgen-Insensitive Prostate Cancer
por: Baust, John G., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_amvl8qpb8gbbnpm2ljf0da4uhf